Moreover, IFN-γ-producing T-bet+Foxp3+ cells did not change following the addition to rapamycin of etomoxir, a fatty acid β oxidation inhibitor, but was significantly inhibited by C75, a fatty acid synthesis inhibitor in both HDs and SLE patients (Figure 5B, Supplementary Figure 4A). The gene discussed is FOXP3; the disease is systemic lupus erythematosus.